The DAYBREAK data significantly de-risk the Zenkuda BLA submission planned for Q4 2026. Monitor for the BLA filing and subsequent FDA acceptance, as well as the KSI-101 topline readout in December 2026, which could further derisk the pipeline.
Price Chart
Executive Summary
Kodiak Sciences announced positive topline Phase 3 DAYBREAK results for both Zenkuda (tarcocimab tedromer) and tabirafusp-ted (KSI-501) in wet age-related macular degeneration. Both met their primary vision endpoints with non-inferiority vs aflibercept; Zenkuda showed 54% of patients on 6-month dosing with a 0% intraocular inflammation rate. A multi-indication BLA submission for Zenkuda is planned for Q4 2026.
Key Facts
- Zenkuda met the primary endpoint (p-value 0.0007) with non-inferiority in vision gains vs aflibercept at year one.
- 54% of Zenkuda patients achieved 6-month dosing durability at year one under strict treat-to-dryness retreatment criteria.
- Zenkuda showed 0% intraocular inflammation rate and 0.5% cataract adverse event rate (vs 0.9% for aflibercept).
- Tabirafusp-ted met the vision primary endpoint (p-value 0.0036) and anatomical key secondary endpoint (p-value <0.0001).
- Kodiak plans to submit a multi-indication BLA for Zenkuda in Q4 2026, covering five positive Phase 3 studies across wAMD, diabetic retinopathy, and retinal vein occlusion.
- Tabirafusp-ted is advancing into the Phase 3 ALTO study in diabetic macular edema, now enrolling patients.
- Topline data for KSI-101 in macular edema secondary to inflammation (MESI) expected December 2026.
Financial Impact
No financial figures provided in the filing. The positive Phase 3 data de-risks the BLA submission and potential commercialization of Zenkuda across three indications, representing a material pipeline value inflection for this pre-revenue biotech.
Risk Factors
- BLA submission and approval are not guaranteed; the FDA may require additional data or reject the filing.
- Commercial launch execution risk for a pre-commercial company with no prior sales infrastructure.
- Competition from existing anti-VEGF therapies (aflibercept, faricimab) with established market positions.
- Tabirafusp-ted's superiority hypothesis in DME remains unproven until the ALTO study reads out.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-403481 |
| Document: d185059d8k.htm | 0001193125-26-403481 |
| Document: 0001193125-26-403481-index-headers.html | 0001193125-26-403481 |
| Document: 0001193125-26-403481-index.html | 0001193125-26-403481 |
| Document: 0001193125-26-403481.txt | 0001193125-26-403481 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | S-3ASR | $87.72 | awaiting T+20 | — | $90.82 (−3.53%) |
Sep 30, 2026 26d ago | SC 13D/A | $98.46 | awaiting T+20 | — | $90.82 (−7.76%) |
Sep 30, 2026 27d ago | Insider Buy | $98.46 | awaiting T+20 | — | $90.82 (−7.76%) |
Sep 28, 2026 29d ago | 8-K | $89.92 $89.60 | ▼ −0.36% | ▼ −0.32% | $90.82 (+1.00%) |
Aug 13, 2026 10w ago | 8-K | $41.35 $33.14 | ▼ −19.85% | ▼ −17.86% | $90.82 (+119.64%) |
Aug 13, 2026 10w ago | Press Release | $41.35 $33.14 | ▼ −19.85% | ▼ −17.86% | $90.82 (+119.64%) |
Jun 11, 2026 19w ago | Institutional Cluster | $33.97 $40.08 | ▲ +17.99% | ▲ +16.10% | $90.82 (+167.35%) |
May 7, 2026 24w ago | 8-K | $41.01 $31.05 | ▼ −24.29% | ▼ −24.31% | $90.82 (+121.46%) |
Mar 31, 2026 29w ago | 8-K | $42.81 $43.67 | ▲ +2.01% | ▼ −7.71% | $90.82 (+112.15%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers